Regional Differences in Human Immunodeficiency Virus (HIV) Testing

Learn more about:
Related Clinical Trial
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19 Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ) InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort Etiology of Lymphopenia in Covid19 Infection Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant Pyridostigmine as Immunomodulator in People Living With HIV Regional Differences in Human Immunodeficiency Virus (HIV) Testing Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort Safety Study of IL-7 in HIV-infected Patients (Inspire) Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Patients Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Brief Title

Regional Differences in Human Immunodeficiency Virus (HIV) Testing

Official Title

Regional Differences in Human Immunodeficiency Virus (HIV) Testing Procedures in Eastern German Federal States

Brief Summary

      This retrospective observational study aims at the examination of regional differences in the
      procedure of referral for serological HIV testing between eastern (new) and western (old)
      German federal states.
    

Detailed Description

      Increasing incidence of HIV infections urges early recognition and timely introduction of
      therapy. Regional differences in referral approach and patient behavior are presumably
      associated with considerable delays in infection recognition and therapy onset. Comparison of
      records of new cases which were diagnosed in 2014 in several eastern federal states and a
      major western German city is expected to disclose whether the regionally preferred type of
      the primary care institution affects the time point of first diagnosis and the elapsed time
      since the emergence of the infection, as assessed by Cluster of Differentiation 4 positive
      (CD4+) lymphocyte counts and manifestation of clinical symptoms of immune deficiency.
    


Study Type

Observational


Primary Outcome

Type of HIV-verifying medical institution

Secondary Outcome

 CD4+ lymphocyte counts

Condition

HIV Seropositivity

Intervention

Medical record review


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

999

Start Date

June 1, 2017

Completion Date

January 30, 2019

Primary Completion Date

January 30, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  first-time HIV seropositivity

        Exclusion Criteria:

          -  N/A
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Benjamin Schleenvoigt, M.D., , 

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT03158987

Organization ID

ZKS00


Responsible Party

Sponsor

Study Sponsor

Jena University Hospital

Collaborators

 University of Magdeburg

Study Sponsor

Benjamin Schleenvoigt, M.D., Study Director, University Hospital Jena


Verification Date

May 2017